A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients - Article Azidothymidine Capsule; AZT Capsule; Compound S Capsule; Retrovir Capsule
Clinical Trial: A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients
This study has been completed.
|Condition||Treatment or Intervention||Phase|
|HIV Infections || Drug: Saquinavir |
|Phase II |
MedlinePlus related topics: AIDS
Study Type: Interventional
Study Design: Treatment, Safety Study
Expected Total Enrollment: 30
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Patients must have:
- HIV antibody positive.
- CD4 count >= 150 and <= 500 cells/mm3.
Prior Medication: Excluded:
- Prior antiretroviral therapy.
- Prior protease inhibitor therapy.
Davies Med Ctr / c/o HIV Institute, San Francisco, California, 94114, United States
Pacific Oaks Med Group / Rsch & Scientific Investigation, Sherman Oaks, California, 91403, United States
Columbia Presbyterian Med Ctr, New York, New York, 10032, United States
Record last reviewed: July 1997
Last Updated: October 13, 2004
Record first received: November 2, 1999
ClinicalTrials.gov Identifier: NCT00002190
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Cache Date: April 9, 2005